Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Nurix Therapeutics's price to sales ratio was 2.5× on Nov 11, 2026, against 16.2× a year earlier. Over the last 5 years it ranged from 2.5× to 72.7×, with a median of 15.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.5× | −14.9 |
| 2025 | Dec 31, 2025 | 17.4× | −5.0 |
| 2024 | Dec 31, 2024 | 22.4× | +15.1 |
| 2023 | Dec 29, 2023 | 7.3× | −5.9 |
| 2022 | Dec 30, 2022 | 13.2× | −31.2 |
| 2021 | Dec 31, 2021 | 44.4× | −53.9 |
| 2020 | Dec 31, 2020 | 98.3× | – |
See a number that looks wrong?